Targeted Radionuclide Therapy

Abstract

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.

Stability and in vivo behavior of Rh[16aneS 4 -diol] 211 At complex: A potential precursor for astatine radiopharmaceuticals

“…TRT is a promising approach for cancer treatment because curative doses of radiation potentially can be selectively delivered not only to the primary tumor but also to metastatic lesions spread throughout the body. Various combinations of targeting vehicles and radionuclides have been investigated, including peptides, intact monoclonal antibodies (mAbs), as well as mAb fragments of various sizes [1]. Most therapeutic investigations have employed radionuclides that emit β − -particles, such as 90 Y, 131 I, or 177 Lu [1,2]; however, due to the long range of β − -particles in tissue, over several millimeters, these radionuclides are best suited for treatment of larger tumors.…”

Therapeutic radionuclides in nuclear medicine: current and future prospects

“…Radionuclides that emit energetic α-or β-particles are preferred for the treatment of bulky tumours. However, for the treatment of small clusters of cancer cells or small tumour deposits, radionuclides that emit Äuger electrons are considered to be more beneficial because of their high-level cytotoxicity and short-range biological effectiveness (Ersahin et al, 2011).…”

“…In the last twenty years, radionuclide therapy has been widely used in various clinical malignant and pain management applications (Hoefnagel, 1991;Nakabeppu and Nakajo, 1994;vande Streek et al, 1994;Forrer et al, 2006;Williams et al, 2008;Lambert et al, 2010;Nestor, 2010;Chiacchio et al, 2011;Ersahin et al, 2011;Carrasquillo et al, 2012;Ezziddin et al, 2012;Gabriel, 2012;Gulenchyn et al, 2012;Dash et al, 2013;Sainz-Esteban and Baum, 2013). Radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tumour while sparing the surrounding normal tissues.…”

Radiochemical Separation of ¹⁶¹Tb from Gd/Tb Matrix Using Ln Resin Column

“…World Health Organization (WHO) declared that cancer patients are increasing every year and two-thirds of them are come from developing countries, including Indonesia [3]. Endoradiotherapy or targeted radionuclide therapy is an evolving and promising modality of cancer treatment [4]. The killing of cancer cells is achieved using biological vectors and appropriate radionuclides [4][5][6].…”

“…Endoradiotherapy or targeted radionuclide therapy is an evolving and promising modality of cancer treatment [4]. The killing of cancer cells is achieved using biological vectors and appropriate radionuclides [4][5][6]. Antibodies and antibody fragments as well as peptides are used as tracer molecules [5,7].…”